In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Aura Biosciences Inc (AURA – Research Report), with a price target of $23.00.
Oliver McCammon has given his Buy rating due to a combination of factors related to Aura Biosciences Inc’s promising developments in their ongoing clinical trials. The company is set to present additional data from its Phase 1 trial in non-muscle invasive bladder cancer (NMIBC) at a major urology congress, which is expected to provide further insights into the efficacy and potential of their drug candidate, bel-sar. This drug has shown early signs of efficacy and an immunogenic mechanism of action, which are encouraging indicators for its future development.
Furthermore, the anticipated data update is likely to shed light on the clinical profile of bel-sar and its development path, including plans for a Phase 1b/2 trial expansion. The positive early signals from the single low dose of bel-sar, along with expert opinions suggesting a broad immune effect, position the drug as a promising candidate for higher-grade NMIBC and potentially muscle-invasive bladder cancer (MIBC) patients. These factors contribute to McCammon’s optimistic outlook and Buy rating for Aura Biosciences Inc.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $22.00 price target.